KR100491282B1 - 통증 치료용 이소부틸가바 및 그의 유도체 - Google Patents
통증 치료용 이소부틸가바 및 그의 유도체 Download PDFInfo
- Publication number
- KR100491282B1 KR100491282B1 KR10-1999-7000577A KR19997000577A KR100491282B1 KR 100491282 B1 KR100491282 B1 KR 100491282B1 KR 19997000577 A KR19997000577 A KR 19997000577A KR 100491282 B1 KR100491282 B1 KR 100491282B1
- Authority
- KR
- South Korea
- Prior art keywords
- pain
- composition
- treated
- gabapentin
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 47
- 230000036407 pain Effects 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000001356 surgical procedure Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 15
- 208000004296 neuralgia Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 2
- 235000013922 glutamic acid Nutrition 0.000 abstract description 2
- 239000004220 glutamic acid Substances 0.000 abstract description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 63
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 60
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 35
- 210000002683 foot Anatomy 0.000 description 33
- 229960002870 gabapentin Drugs 0.000 description 29
- 241000700159 Rattus Species 0.000 description 22
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 229960005181 morphine Drugs 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 229920001525 carrageenan Polymers 0.000 description 14
- 235000010418 carrageenan Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000003447 ipsilateral effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000035154 Hyperesthesia Diseases 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 208000004550 Postoperative Pain Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000692 Student's t-test Methods 0.000 description 6
- 239000000679 carrageenan Substances 0.000 description 6
- 229940113118 carrageenan Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- 206010053552 allodynia Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- -1 n-bufil Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003574 anti-allodynic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MNBODUCODDEXEE-UHFFFAOYSA-N ethyl 4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C MNBODUCODDEXEE-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- OBLVSONFNRLRIQ-UHFFFAOYSA-N lithium;ethyl acetate Chemical compound [Li+].CCOC([CH2-])=O OBLVSONFNRLRIQ-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 231100000878 neurological injury Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2233796P | 1996-07-24 | 1996-07-24 | |
| US60/022,337 | 1996-07-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20000068015A KR20000068015A (ko) | 2000-11-25 |
| KR100491282B1 true KR100491282B1 (ko) | 2005-05-24 |
Family
ID=21809080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-1999-7000577A Expired - Lifetime KR100491282B1 (ko) | 1996-07-24 | 1997-07-16 | 통증 치료용 이소부틸가바 및 그의 유도체 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | USRE41920E1 (enExample) |
| EP (1) | EP0934061B3 (enExample) |
| JP (1) | JP3693258B2 (enExample) |
| KR (1) | KR100491282B1 (enExample) |
| CN (1) | CN1094757C (enExample) |
| AT (1) | ATE241351T1 (enExample) |
| AU (1) | AU714980B2 (enExample) |
| BR (1) | BR9710536A (enExample) |
| CU (1) | CU22850A3 (enExample) |
| DE (1) | DE69722426T3 (enExample) |
| DK (1) | DK0934061T6 (enExample) |
| ES (1) | ES2200184T7 (enExample) |
| HR (1) | HRP970387A2 (enExample) |
| HU (2) | HU228426B1 (enExample) |
| IL (1) | IL126999A (enExample) |
| NO (2) | NO325822B1 (enExample) |
| NZ (1) | NZ332762A (enExample) |
| PL (1) | PL189872B1 (enExample) |
| PT (1) | PT934061E (enExample) |
| SI (1) | SI0934061T1 (enExample) |
| WO (1) | WO1998003167A1 (enExample) |
| ZA (1) | ZA976562B (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| AU750578B2 (en) * | 1997-09-08 | 2002-07-25 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| HU228771B1 (en) * | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| CA2332927A1 (en) * | 1998-07-09 | 2000-01-20 | Catherine A. Segal | Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain |
| ATE279188T1 (de) * | 1998-07-09 | 2004-10-15 | Warner Lambert Co | Pharmazeutische zusammensetzungen enthaltend gaba-analogen und ein antivirales mittel zur behandlung von herpes zoster |
| BR9911925A (pt) * | 1998-07-09 | 2001-03-27 | Warner Lambert Co | O tratamento de cólica renal com análogos de gaba |
| US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| WO2000067742A2 (en) * | 1999-05-05 | 2000-11-16 | Warner-Lambert Company | Use of gaba analogues for the modulation of substance p |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| JP3904452B2 (ja) * | 1999-06-10 | 2007-04-11 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | モノ−およびジ置換３−プロピルガンマ−アミノ酪酸 |
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| SK287303B6 (sk) * | 2000-01-27 | 2010-06-07 | Warner-Lambert Company | Spôsob prípravy derivátu (S)-3-kyano-5-metyl-hexánovej kyseliny, spôsob a medziprodukt na prípravu pregabalínu |
| US6687187B2 (en) * | 2000-08-11 | 2004-02-03 | Phonak Ag | Method for directional location and locating system |
| CA2356829A1 (en) * | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| PT1243262E (pt) * | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| EP1243263B1 (en) * | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2002100347A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
| WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| CA2459470C (en) * | 2001-09-03 | 2010-10-12 | Patricia Salvati | Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use |
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US20040162351A1 (en) * | 2002-12-11 | 2004-08-19 | Gallop Mark A. | Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity |
| AU2003297927A1 (en) * | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
| NZ540336A (en) * | 2002-12-13 | 2008-03-28 | Warner Lambert Co | Gabapentin analogues for fibromyalgia and other related disorders |
| EP1572187A1 (en) * | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20050085636A (ko) * | 2002-12-13 | 2005-08-29 | 워너-램버트 캄파니 엘엘씨 | 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체 |
| US20080318908A1 (en) * | 2002-12-17 | 2008-12-25 | Trustees Of Tufts College | Use of gaba and gabab agonists |
| MXPA06002789A (es) | 2003-09-12 | 2006-06-14 | Pfizer | Combinaciones que comprenden ligandos alfa-2-delta. |
| MXPA06003043A (es) * | 2003-09-17 | 2006-05-31 | Xenoport Inc | Tratamiento o prevencion del sindrome piernas inquietas utilizando prodrogas de analogos gaba. |
| WO2005037784A2 (en) * | 2003-10-14 | 2005-04-28 | Xenoport, Inc. | Crystalline form of gamma-aminobutyric acid analog |
| ES2325995T3 (es) * | 2003-12-02 | 2009-09-28 | Schwarz Pharma Ag | Nueva utilizacion de compuestos peptidicos para tratamiento del dolor neuropatico central. |
| DE602005002253T2 (de) * | 2004-03-12 | 2008-05-29 | Warner-Lambert Company Llc | C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| JP2007530657A (ja) * | 2004-04-01 | 2007-11-01 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｐキラル性ホスホランの調製および不斉合成でのその使用 |
| JP2007532607A (ja) | 2004-04-16 | 2007-11-15 | シュバルツ ファルマ アクチェンゲゼルシャフト | 慢性頭痛の予防及び治療のためのペプチド化合物の使用 |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| RS51210B (sr) * | 2004-06-21 | 2010-12-31 | Warner-Lambert Company Llc. | Dobijanje pregaballina i srodnih jedinjenja |
| BRPI0514721A (pt) * | 2004-08-27 | 2008-06-24 | Sanol Arznei Schwarz Gmbh | uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo |
| EP1811986B1 (en) * | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| US7763749B2 (en) * | 2005-05-10 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Method for the preparation of Pregabalin and salts thereof |
| CA2604624A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
| WO2006124609A2 (en) * | 2005-05-16 | 2006-11-23 | Joseph Johnson | Methods and compositions for treating arg |
| KR20080003429A (ko) * | 2005-05-20 | 2008-01-07 | 화이자 리미티드 | 비스테로이드 소염 약물 및 알파-델타-리간드의 상승작용적조합물 |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| ES2398579T3 (es) | 2005-09-19 | 2013-03-20 | Teva Pharmaceutical Industries Ltd | Una síntesis asimétrica de ácido (S)-(+)-3-(aminometil)-5-metilhexanoico |
| TW200815323A (en) * | 2006-05-24 | 2008-04-01 | Teva Pharma | Processes for the preparation of R-(+)-3-(carbamoylmethyl)-5-methylhexanoic acid and salts thereof |
| ES2531118T5 (es) | 2006-06-15 | 2022-06-14 | Ucb Pharma Gmbh | Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia |
| CA2681313C (en) * | 2007-03-22 | 2012-09-11 | Teva Pharmaceutical Industries Ltd. | Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid |
| KR20090101462A (ko) * | 2007-10-03 | 2009-09-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법 |
| US20100087525A1 (en) * | 2008-06-23 | 2010-04-08 | Lilach Hedvati | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010070593A2 (en) | 2008-12-19 | 2010-06-24 | Pfizer Ireland Pharmaceuticals | Malonate esters |
| WO2010099200A1 (en) | 2009-02-24 | 2010-09-02 | Nektar Therapeutics | Oligomer-amino acid conjugates |
| NZ610978A (en) * | 2009-05-15 | 2014-11-28 | Redx Pharma Ltd | Redox drug derivatives |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| IN2012MN02923A (enExample) | 2010-06-01 | 2015-06-05 | Rubicon Res Private Ltd | |
| WO2012025861A1 (en) | 2010-08-23 | 2012-03-01 | Pfizer Manufacturing Ireland | Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin |
| US8466297B2 (en) | 2010-11-01 | 2013-06-18 | Milan Soukup | Manufacturing process for (S)-Pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| WO2013114283A1 (en) | 2012-01-30 | 2013-08-08 | Ranbaxy Laboratories Limited | Gastroretentive tablets |
| EP2809303A1 (en) | 2012-01-30 | 2014-12-10 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
| CN102966602B (zh) * | 2012-12-14 | 2015-08-05 | 江苏海鸥冷却塔股份有限公司 | 一种冷却塔节能导流风筒 |
| US10004710B2 (en) | 2013-01-18 | 2018-06-26 | Kemphys Ltd. | Medicament for therapeutic treatment of neuropathic disease |
| CN105051022B (zh) | 2013-03-27 | 2017-10-27 | 辉瑞爱尔兰制药公司 | 用于制备普瑞巴林的方法和中间体 |
| CA2953225A1 (en) | 2015-05-26 | 2016-12-01 | Isa Odidi | Controlled extended release pregabalin |
| GB201617380D0 (en) * | 2016-10-13 | 2016-11-30 | St George's Hospital Medical School | Treatment for Osteoarthritis |
| KR102039345B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 고팽윤성 서방성 삼중정제 |
| KR102039344B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 경구용 서방성 삼중정제 |
| GB201703123D0 (en) * | 2017-02-27 | 2017-04-12 | St George's Hospital Medical School | Biomarkers |
| AU2019271799B2 (en) | 2018-05-14 | 2023-10-12 | Xgene Pharmaceutical Inc. | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin |
| CN108926573A (zh) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | 一种可降低尿酸指数的nadh组合物及其制备方法及应用 |
| KR20200056719A (ko) | 2018-11-15 | 2020-05-25 | 단국대학교 천안캠퍼스 산학협력단 | 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물 |
| PH12022551856A1 (en) | 2020-01-22 | 2024-01-03 | Seelos Therapeutics Inc | Reducing side effects of nmda antagonists |
| WO2021191108A1 (en) | 2020-03-23 | 2021-09-30 | Plus Vitech, S.L. | Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid |
| WO2022038131A1 (en) | 2020-08-19 | 2022-02-24 | Plus Vitech, S.L. | Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage |
| WO2022157527A1 (en) | 2021-01-22 | 2022-07-28 | Egis Gyógyszergyár Zrt. | Topical formulation containing dispersed pregabalin |
| HU231397B1 (hu) | 2021-01-22 | 2023-06-28 | Egis Gyógyszergyár Zrt. | Pregabalint tartalmazó topikális gyógyszerkészítmény |
| WO2022234110A1 (en) | 2021-05-07 | 2022-11-10 | Plus Vitech, S.L. | Gamma-aminobutyric acid derivatives for use in cancer therapy |
| WO2022243430A1 (en) | 2021-05-20 | 2022-11-24 | Plus Vitech, S.L. | Treatment of acne |
| WO2022253748A1 (en) | 2021-06-03 | 2022-12-08 | Plus Vitech, S.L. | Combinations for the treatment of hpv |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| JPS4940460Y2 (enExample) | 1971-05-19 | 1974-11-06 | ||
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4123438A (en) | 1975-03-05 | 1978-10-31 | Stamicarbon, B.V. | Process for preparing 2-pyrrolidones |
| NZ194348A (en) | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| US4322440A (en) | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
| US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| FI832935A7 (fi) | 1982-08-20 | 1984-02-21 | Midit | Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar |
| US4479005A (en) | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
| WO1985000520A1 (en) | 1983-08-01 | 1985-02-14 | The Mclean Hospital Corporation | Gaba esters and gaba analogue esters |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| GB8425872D0 (en) | 1984-10-12 | 1984-11-21 | Ciba Geigy Ag | Chemical compounds |
| DK170473B1 (da) | 1985-06-20 | 1995-09-11 | Daiichi Seiyaku Co | S(-)-pyridobenzoxazinforbindelser |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| JP2535001B2 (ja) | 1987-01-13 | 1996-09-18 | ダイセル化学工業株式会社 | Ｎ−アルキル化アミノ酸エステルの製法 |
| JPH07116064B2 (ja) | 1987-07-21 | 1995-12-13 | 三菱化学株式会社 | 分離剤 |
| US4908210A (en) | 1988-10-28 | 1990-03-13 | Eastman Kodak Company | Lactylic salt tablet formulations and tablets |
| GB8911017D0 (en) | 1989-05-13 | 1989-06-28 | Ciba Geigy Ag | Substituted aminoalkylphosphinic acids |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| GB8921304D0 (en) | 1989-09-20 | 1989-11-08 | Wyeth John & Brother Ltd | New method of treatment and heterocyclic compounds used therein |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
| WO1992009560A1 (en) | 1990-11-27 | 1992-06-11 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| WO1992014443A1 (en) | 1991-02-20 | 1992-09-03 | Warner-Lambert Company | Microsphere-in-oil emulsion |
| DK204791D0 (da) | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
| JP3856816B2 (ja) | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体 |
| GB9308430D0 (en) | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
| US5492927A (en) | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| MX9606674A (es) | 1994-07-27 | 1997-03-29 | Warner Lambert Co | Tratamiento de enfermedades humanas que involucran la desregulacion o disfuncion del sistema nervioso. |
| US5792796A (en) | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| GB9420784D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| ES2229259T3 (es) | 1995-01-12 | 2005-04-16 | Glaxo Group Limited | Derivados de piperidina con actividad antagonista de taquiquinina. |
| UA43396C2 (uk) | 1995-02-28 | 2001-12-17 | Х. Луннбек, А/С | Похідні 4-амінотетрагідробензізоксазолу та ізотіазолу та фармацевтична композиція на їх основі |
| US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| US5616793A (en) | 1995-06-02 | 1997-04-01 | Warner-Lambert Company | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US5637767A (en) | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| DK0888325T3 (da) | 1996-02-07 | 2002-09-16 | Warner Lambert Co | Cykliske aminosyrer som farmaceutiske midler |
| WO1997033859A1 (en) | 1996-03-14 | 1997-09-18 | Warner-Lambert Company | Novel bridged cyclic amino acids as pharmaceutical agents |
| AU734173B2 (en) | 1996-03-14 | 2001-06-07 | Warner-Lambert Company | Novel substituted cyclic amino acids as pharmaceutical agents |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| NZ333062A (en) | 1996-06-26 | 2000-06-23 | Warner Lambert Co | Use of [R,S]-[2-(1H-indol-3-yl)-1-methyl-1-(1-phenyl-ethylcarbamoyl)-ethyl]-carbamic acid benzofuran-2yl methyl ester in the treatment of emesis |
| SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| WO1999008667A2 (en) | 1997-08-19 | 1999-02-25 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
| US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| AU750578B2 (en) | 1997-09-08 | 2002-07-25 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| JP2002508361A (ja) | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | （（シクロ）アルキル置換）−γ−アミノ酪酸誘導体（＝ＧＡＢＡ類似体）、それらの製造および神経学的疾患の治療における使用 |
| BR9910494B1 (pt) | 1998-05-15 | 2011-11-01 | composições sólidas contendo derivados de ácido gama-aminobutìrico e processo para o seu preparo. | |
| HU228771B1 (en) | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| NZ508490A (en) | 1998-07-09 | 2003-08-29 | Warner Lambert Co | Use of a combination of a GABA analog and caffeine as an analgesic |
| US20030045500A1 (en) | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| JP2002520277A (ja) | 1998-07-09 | 2002-07-09 | ワーナー−ランバート・カンパニー | 不眠症を治療する方法 |
| DK1121114T3 (da) | 1998-10-16 | 2007-04-10 | Warner Lambert Co | Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser |
| US6451857B1 (en) | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| IL145736A0 (en) | 1999-04-09 | 2002-07-25 | Warner Lambert Co | Combinations of gaba analogs and tricyclic compounds to treat depression |
| PT1187832E (pt) | 1999-06-02 | 2003-03-31 | Warner Lambert Co | Amino heterociclos uteis como agentes farmaceuticos |
| US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| MXPA02000170A (es) | 1999-07-02 | 2002-07-02 | Warner Lambert Co | Una combinacion sinergica: gabapentin y pregablin. |
| US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| CA2384911C (en) | 1999-09-16 | 2008-07-22 | Warner-Lambert Company | Method for the screening of .alpha.2. delta.-1 subunit binding ligands |
| AP2002002501A0 (en) | 1999-10-07 | 2002-06-30 | Warner Lambert Co | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. |
| SK287303B6 (sk) | 2000-01-27 | 2010-06-07 | Warner-Lambert Company | Spôsob prípravy derivátu (S)-3-kyano-5-metyl-hexánovej kyseliny, spôsob a medziprodukt na prípravu pregabalínu |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| WO2001088101A2 (en) | 2000-05-16 | 2001-11-22 | Warner-Lambert Company | CELL LINE FOR THE EXPRESSION OF AN α2δ2 CALCIUM CHANNEL SUBUNIT |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| CA2356829A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| AP2001002360A0 (en) | 2000-11-30 | 2001-12-31 | Pfizer Prod Inc | Combination of gaba agonists and sorbitol dehydrogenase inhibitors. |
| CA2430309A1 (en) | 2000-11-30 | 2002-06-06 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
| EP1341799B1 (en) | 2000-12-13 | 2005-03-16 | Warner-Lambert Company LLC | P-chirale bisphospholane ligands, their transition metal complexes |
| US20040002543A1 (en) | 2001-02-16 | 2004-01-01 | Leslie Magnus | Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain |
| ES2240657T3 (es) | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| MXPA02001147A (es) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica. |
| CA2442476A1 (en) | 2001-03-30 | 2002-10-10 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| EA006396B1 (ru) | 2001-04-19 | 2005-12-29 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си | Конденсированные бициклические аминокислоты |
| DE60213592T2 (de) | 2001-05-25 | 2007-08-09 | Warner-Lambert Co. Llc | Flüssige pharmazeutische zusammensetzung |
| US20030045449A1 (en) | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| DE10203122A1 (de) | 2002-01-25 | 2003-07-31 | Gruenenthal Gmbh | Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren |
| KR20040081478A (ko) | 2002-01-31 | 2004-09-21 | 워너-램버트 캄파니 엘엘씨 | 이명을 치료하기 위한 알파 2 델타 리간드 |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| US20030225149A1 (en) | 2002-04-30 | 2003-12-04 | Blazecka Peter G. | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids |
| AU2003239752A1 (en) | 2002-06-27 | 2004-01-19 | Warner-Lambert Company Llc | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7071339B2 (en) | 2002-08-29 | 2006-07-04 | Warner Lambert Company Llc | Process for preparing functionalized γ-butyrolactones from mucohalic acid |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| BR0316386A (pt) | 2002-12-06 | 2005-09-27 | Warner Lambert Co | Benzoxazin-3-onas e seus derivados como inibidores de p13k |
| EP1572187A1 (en) | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| EP1633400A2 (en) | 2003-05-16 | 2006-03-15 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| EP1644360A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | 3-substituted indoles and derivatives thereof as therapeutic agents |
| EP1680125A1 (en) | 2003-07-02 | 2006-07-19 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| ATE539077T1 (de) | 2003-09-03 | 2012-01-15 | Pfizer | Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor |
| MXPA06002789A (es) | 2003-09-12 | 2006-06-14 | Pfizer | Combinaciones que comprenden ligandos alfa-2-delta. |
| AU2004271796A1 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| CA2540247C (en) | 2003-09-25 | 2011-01-25 | Warner-Lambert Company Llc | Prodrugs of amino acids with affinity for the .alpha.2.delta.-protein |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| EP1543831A1 (en) | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| EP1737466A1 (en) | 2004-01-29 | 2007-01-03 | Pfizer Products Inc. | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| DE602005002253T2 (de) | 2004-03-12 | 2008-05-29 | Warner-Lambert Company Llc | C1-symmetrische bisphosphinliganden und deren verwendung bei der asymmetrischen synthese von pregabalin |
| WO2005092858A2 (en) | 2004-03-29 | 2005-10-06 | Pfizer Japan Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist |
| JP2007530657A (ja) | 2004-04-01 | 2007-11-01 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｐキラル性ホスホランの調製および不斉合成でのその使用 |
| CA2562251C (en) | 2004-04-07 | 2009-04-28 | Pfizer Inc. | Pyrazolo'4,3-d pyrimidines |
| UA82292C2 (uk) | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти) |
| BRPI0510043A (pt) | 2004-04-20 | 2007-10-16 | Pfizer | método de tratamento de dor neuropática usando antagonista de receptor crth2 |
| CA2563356A1 (en) | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| AP2006003771A0 (en) | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| BRPI0512046A (pt) | 2004-06-15 | 2008-02-06 | Pfizer | derivados de ácido benzimidazolona carboxìlico |
| RS51210B (sr) | 2004-06-21 | 2010-12-31 | Warner-Lambert Company Llc. | Dobijanje pregaballina i srodnih jedinjenja |
| JP2008504360A (ja) | 2004-06-29 | 2008-02-14 | ファイザー・プロダクツ・インク | ヒドロキシル保護された前駆体を脱保護することによる５−［４−（２−ヒドロキシ−プロピル）−３，５−ジオキソ−４，５−ジヒドロ−３ｈ−１，２，４−トリアジン−２−イル］−ベンズアミド誘導体の製造方法 |
| US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| WO2006008640A1 (en) | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| BRPI0513717A (pt) | 2004-07-23 | 2008-05-13 | Pfizer | derivados de piridina |
| GB0419849D0 (en) | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
| ATE417830T1 (de) | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| CN101111494A (zh) | 2004-11-29 | 2008-01-23 | 沃纳-兰伯特有限公司 | 具有治疗作用的吡唑并[3,4-b]吡啶和吲唑 |
| NZ556627A (en) | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| CA2600409C (en) | 2005-03-10 | 2011-07-05 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
| AP2007004157A0 (en) | 2005-03-17 | 2007-10-31 | Pfizer | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain |
| CA2604218A1 (en) | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| EA200701852A1 (ru) | 2005-04-28 | 2008-04-28 | Пфайзер Лимитед | Производные аминокислот |
| KR20080003429A (ko) | 2005-05-20 | 2008-01-07 | 화이자 리미티드 | 비스테로이드 소염 약물 및 알파-델타-리간드의 상승작용적조합물 |
| JP2008542355A (ja) | 2005-05-31 | 2008-11-27 | ファイザー株式会社 | Ｖｒ１アンタゴニストとしての置換アリールオキシ−ｎ−ビシクロメチルアセトアミド化合物 |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| CA2628844C (en) | 2005-11-08 | 2011-12-06 | Pfizer Limited | Pyrazole derivatives and their medical use |
| CA2631535C (en) | 2005-12-02 | 2010-07-27 | Pfizer Limited | Spirocyclic quinazoline derivatives as pde7 inhibitors |
| CA2530904C (en) | 2005-12-20 | 2013-10-08 | John Marino | Pharmaceutical agents for the treatment of pain associated with spinal cord injury |
| RU2008135907A (ru) | 2006-03-06 | 2010-04-20 | Пфайзер Продактс Инк. (Us) | Альфа-2-дельта лиганды для невосстановительного сна |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| ATE518872T1 (de) | 2007-02-02 | 2011-08-15 | Pfizer Prod Inc | Trizyklische verbindungen und deren verwendung als glucocorticoidrezeptormodulatoren |
| WO2008132589A1 (en) | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
-
1997
- 1997-07-16 KR KR10-1999-7000577A patent/KR100491282B1/ko not_active Expired - Lifetime
- 1997-07-16 US US11/983,750 patent/USRE41920E1/en not_active Expired - Lifetime
- 1997-07-16 CN CN97196041A patent/CN1094757C/zh not_active Expired - Lifetime
- 1997-07-16 ES ES97932617.0T patent/ES2200184T7/es active Active
- 1997-07-16 US US09/043,358 patent/US6001876A/en not_active Expired - Lifetime
- 1997-07-16 WO PCT/US1997/012390 patent/WO1998003167A1/en not_active Ceased
- 1997-07-16 JP JP50706298A patent/JP3693258B2/ja not_active Expired - Lifetime
- 1997-07-16 PL PL97331325A patent/PL189872B1/pl unknown
- 1997-07-16 SI SI9730545T patent/SI0934061T1/xx unknown
- 1997-07-16 AT AT97932617T patent/ATE241351T1/de active
- 1997-07-16 DK DK97932617.0T patent/DK0934061T6/en active
- 1997-07-16 IL IL12699997A patent/IL126999A/en not_active IP Right Cessation
- 1997-07-16 PT PT97932617T patent/PT934061E/pt unknown
- 1997-07-16 EP EP97932617.0A patent/EP0934061B3/en not_active Expired - Lifetime
- 1997-07-16 BR BR9710536A patent/BR9710536A/pt not_active Application Discontinuation
- 1997-07-16 AU AU36024/97A patent/AU714980B2/en not_active Expired
- 1997-07-16 HU HU9904361A patent/HU228426B1/hu active Protection Beyond IP Right Term
- 1997-07-16 DE DE1997622426 patent/DE69722426T3/de not_active Expired - Lifetime
- 1997-07-16 NZ NZ332762A patent/NZ332762A/xx not_active IP Right Cessation
- 1997-07-17 HR HR60/022,337A patent/HRP970387A2/hr not_active Application Discontinuation
- 1997-07-23 ZA ZA9706562A patent/ZA976562B/xx unknown
-
1999
- 1999-01-22 CU CU1999008A patent/CU22850A3/es unknown
- 1999-01-22 NO NO19990279A patent/NO325822B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 NO NO2008018C patent/NO2008018I2/no unknown
-
2013
- 2013-08-27 HU HUS1300046C patent/HUS1300046I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100491282B1 (ko) | 통증 치료용 이소부틸가바 및 그의 유도체 | |
| JP4154237B2 (ja) | 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用 | |
| AU2002257680A1 (en) | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | |
| JP4867123B2 (ja) | 神経因性疼痛治療剤および神経因性疼痛のモデル動物 | |
| CA2255652E (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| US11419833B2 (en) | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders | |
| HK1021134B (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| CN113855658A (zh) | 用于治疗癫痫和相关病症的经鼻给药的药物组合物 | |
| HK1143088A (en) | Novel use of a peptide class of compounds for treating diabetic neuropathic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19990123 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20020716 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20041013 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20050309 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050516 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20050517 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20080407 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090409 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100429 Start annual number: 6 End annual number: 6 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20110307 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20110307 Decision date: 20121031 Appeal identifier: 2011100000490 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110428 Start annual number: 7 End annual number: 7 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20110523 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20110523 Decision date: 20121031 Appeal identifier: 2011100001157 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20110609 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20110609 Decision date: 20121031 Appeal identifier: 2011100001318 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20110614 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20110614 Decision date: 20121031 Appeal identifier: 2011100001369 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20110905 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20110905 Decision date: 20121031 Appeal identifier: 2011100002127 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20111109 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20111109 Decision date: 20121031 Appeal identifier: 2011100002836 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20111130 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20111130 Decision date: 20121031 Appeal identifier: 2011100003024 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20120117 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20120117 Decision date: 20121106 Appeal identifier: 2012100000170 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120427 Start annual number: 8 End annual number: 8 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20111130 Effective date: 20121031 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20111109 Effective date: 20121031 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110523 Effective date: 20121031 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110614 Effective date: 20121031 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110609 Effective date: 20121031 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110905 Effective date: 20121031 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110307 Effective date: 20121031 |
|
| PJ1301 | Trial decision |
Appeal kind category: Invalidation Request date: 20111130 Decision date: 20121031 Appeal identifier: 2011100003024 Appeal kind category: Invalidation Request date: 20111109 Decision date: 20121031 Appeal identifier: 2011100002836 Appeal kind category: Invalidation Request date: 20110905 Decision date: 20121031 Appeal identifier: 2011100002127 Appeal kind category: Invalidation Request date: 20110614 Decision date: 20121031 Appeal identifier: 2011100001369 Appeal kind category: Invalidation Request date: 20110609 Decision date: 20121031 Appeal identifier: 2011100001318 Appeal kind category: Invalidation Request date: 20110523 Decision date: 20121031 Appeal identifier: 2011100001157 Patent event code: PJ13011S08D Patent event date: 20121031 Comment text: Consolidated Trial Decision Appeal kind category: Invalidation Request date: 20110307 Decision date: 20121031 Appeal identifier: 2011100000490 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20121101 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20121101 Decision date: 20121105 Appeal identifier: 2012100002843 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20121102 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20121102 Decision date: 20131206 Appeal identifier: 2012100002857 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20121105 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2012100002843 Request date: 20121101 Appeal kind category: Invalidation Decision date: 20121105 |
|
| PJ2001 | Appeal |
Patent event date: 20121031 Comment text: Consolidated Trial Decision Patent event code: PJ20011S08I Appeal kind category: Invalidation Decision date: 20131010 Appeal identifier: 2012200009839 Request date: 20121105 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20120117 Effective date: 20121106 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S05D Patent event date: 20121106 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Appeal kind category: Invalidation Request date: 20120117 Decision date: 20121106 Appeal identifier: 2012100000170 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION |
|
| PJ2001 | Appeal |
Patent event date: 20121106 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121031 Comment text: Consolidated Trial Decision Patent event code: PJ20011S08I Appeal kind category: Invalidation Decision date: 20131010 Appeal identifier: 2012200010563 Request date: 20121129 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION |
|
| PJ2001 | Appeal |
Appeal kind category: Invalidation Decision date: 20131010 Appeal identifier: 2012200010679 Request date: 20121130 Patent event date: 20121106 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121031 Comment text: Consolidated Trial Decision Patent event code: PJ20011S08I Appeal kind category: Invalidation Decision date: 20131010 Appeal identifier: 2012200010631 Request date: 20121130 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION |
|
| PJ2001 | Appeal |
Patent event date: 20121106 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121031 Comment text: Consolidated Trial Decision Patent event code: PJ20011S08I Appeal kind category: Invalidation Decision date: 20131010 Appeal identifier: 2012200010754 Request date: 20121206 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130429 Start annual number: 9 End annual number: 9 |
|
| J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20121129 Effective date: 20131010 Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20121130 Effective date: 20131010 Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20121206 Effective date: 20131010 Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20121105 Effective date: 20131010 |
|
| PJ1302 | Judgment (patent court) |
Request date: 20121206 Decision date: 20131010 Appeal identifier: 2012200010754 Appeal kind category: Invalidation Request date: 20121130 Decision date: 20131010 Appeal identifier: 2012200010679 Appeal kind category: Invalidation Request date: 20121130 Decision date: 20131010 Appeal identifier: 2012200010631 Appeal kind category: Invalidation Request date: 20121129 Decision date: 20131010 Appeal identifier: 2012200010563 Appeal kind category: Invalidation Patent event date: 20131104 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 20121105 Decision date: 20131010 Appeal identifier: 2012200009839 Appeal kind category: Invalidation |
|
| J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION |
|
| PJ2002 | Appeal before the supreme court |
Request date: 20131106 Appeal identifier: 2013300002880 Appeal kind category: Invalidation Decision date: 20160114 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event date: 20121106 Patent event code: PJ20021S05I Comment text: Consolidated Trial Decision Patent event date: 20121031 Patent event code: PJ20021S08I Request date: 20131106 Appeal identifier: 2013300002873 Appeal kind category: Invalidation Decision date: 20160114 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20131206 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2012100002857 Request date: 20121102 Appeal kind category: Invalidation Decision date: 20131206 |
|
| FPAY | Annual fee payment |
Payment date: 20140430 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140430 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150330 Start annual number: 11 End annual number: 11 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20160113 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 20050516 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20160113 Decision date: 20160520 Appeal identifier: 2016100000105 |
|
| J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20131106 Effective date: 20160114 |
|
| PJ1303 | Judgment (supreme court) |
Decision date: 20160114 Appeal kind category: Invalidation Request date: 20131106 Appeal identifier: 2013300002880 Comment text: Written Judgment (Supreme Court) Patent event date: 20160122 Patent event code: PJ13031S01D Decision date: 20160114 Appeal kind category: Invalidation Request date: 20131106 Appeal identifier: 2013300002873 |
|
| PG1701 | Publication of correction |
Publication date: 20160205 |
|
| PG1701 | Publication of correction |
Publication date: 20160205 |
|
| FPAY | Annual fee payment |
Payment date: 20160330 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160330 Start annual number: 12 End annual number: 12 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20160113 Effective date: 20160520 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S05D Patent event date: 20160520 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Appeal kind category: Invalidation Request date: 20160113 Decision date: 20160520 Appeal identifier: 2016100000105 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION |
|
| PJ2001 | Appeal |
Patent event date: 20160520 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121106 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121031 Comment text: Consolidated Trial Decision Patent event code: PJ20011S08I Appeal kind category: Invalidation Decision date: 20160930 Appeal identifier: 2016200004405 Request date: 20160621 |
|
| PJ2002 | Appeal before the supreme court |
Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event date: 20160520 Patent event code: PJ20021S05I Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event date: 20121106 Patent event code: PJ20021S05I Comment text: Consolidated Trial Decision Patent event date: 20121031 Patent event code: PJ20021S08I Request date: 20161028 Appeal identifier: 2016300002317 Appeal kind category: Invalidation Decision date: 20200429 |
|
| J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2016200004405; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20160621 Effective date: 20160930 |
|
| PJ1302 | Judgment (patent court) |
Patent event date: 20161110 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 20160621 Decision date: 20160930 Appeal identifier: 2016200004405 Appeal kind category: Invalidation |
|
| PR1001 | Payment of annual fee |
Payment date: 20170330 Start annual number: 13 End annual number: 13 |
|
| PC1801 | Expiration of term | ||
| J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2016300002317; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20161028 Effective date: 20200429 |
|
| PJ1303 | Judgment (supreme court) |
Comment text: Written Judgment (Supreme Court) Patent event date: 20200508 Patent event code: PJ13031S01D Decision date: 20200429 Appeal kind category: Invalidation Request date: 20161028 Appeal identifier: 2016300002317 |
|
| PJ2201 | Remand (intellectual property tribunal) |
Request date: 20200508 Appeal kind category: Invalidation Appeal identifier: 2020130000078 Decision date: 20210924 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020130000078; TRIAL DECISION FOR INVALIDATION REQUESTED 20200508 Effective date: 20210924 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S09D Patent event date: 20210924 Comment text: Trial Decision on Final Judgment on Revocation Appeal kind category: Invalidation Request date: 20200508 Decision date: 20210924 Appeal identifier: 2020130000078 |
|
| PJ2001 | Appeal |
Patent event date: 20210924 Comment text: Trial Decision on Final Judgment on Revocation Patent event code: PJ20011S09I Patent event date: 20160520 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121106 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Patent event date: 20121031 Comment text: Consolidated Trial Decision Patent event code: PJ20011S08I Appeal kind category: Invalidation Decision date: 20221101 Appeal identifier: 2021200006221 Request date: 20211123 |
|
| J121 | Written withdrawal of request for trial | ||
| PJ1201 | Withdrawal of trial |
Appeal identifier: 2020130000078 Request date: 20200508 Appeal kind category: Invalidation Decision date: 20210924 Patent event code: PJ12011R01D Patent event date: 20221027 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2016100000105 Request date: 20160113 Appeal kind category: Invalidation Decision date: 20160520 |
|
| J122 | Written withdrawal of action (patent court) | ||
| PJ1202 | Withdrawal of action (patent court) |
Patent event code: PJ12021R01D Patent event date: 20221109 Comment text: Written Withdrawal of Action Decision date: 20221101 Request date: 20211123 Appeal identifier: 2021200006221 Appeal kind category: Invalidation |